With persistent effort, the IMpower133 randomized double-blind phase III trial revealed that the addition of atezolizumab, an anti-PD-L1 antibody, to standard chemotherapy could significantly prolong the median OS in patients with ES-SCLC for 2 months [4]. This evidence concerns the gene CD274 and small cell lung carcinoma.